Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Celldex Therapeutics (CLDX) Accounts Payables (2016 - 2025)

Celldex Therapeutics has reported Accounts Payables over the past 16 years, most recently at $1.2 million for Q4 2025.

  • Quarterly results put Accounts Payables at $1.2 million for Q4 2025, down 63.86% from a year ago — trailing twelve months through Dec 2025 was $1.2 million (down 63.86% YoY), and the annual figure for FY2025 was $1.2 million, down 63.86%.
  • Accounts Payables for Q4 2025 was $1.2 million at Celldex Therapeutics, down from $4.3 million in the prior quarter.
  • Over the last five years, Accounts Payables for CLDX hit a ceiling of $4.3 million in Q3 2025 and a floor of $685000.0 in Q2 2021.
  • Median Accounts Payables over the past 5 years was $2.2 million (2022), compared with a mean of $2.2 million.
  • Peak annual rise in Accounts Payables hit 331.56% in 2024, while the deepest fall reached 68.93% in 2024.
  • Celldex Therapeutics' Accounts Payables stood at $1.2 million in 2021, then surged by 171.99% to $3.3 million in 2022, then rose by 4.61% to $3.5 million in 2023, then decreased by 6.55% to $3.3 million in 2024, then crashed by 63.86% to $1.2 million in 2025.
  • The last three reported values for Accounts Payables were $1.2 million (Q4 2025), $4.3 million (Q3 2025), and $2.1 million (Q2 2025) per Business Quant data.